Black Friday Special: Could 12/1 be the most profitable event in crypto history?
Man voted "#1 Most Trusted Crypto Expert" shares his latest buy recommendation.
Click For Special

AYLA Insider Trading (Ayala Pharmaceuticals)

Insider Ownership Percentage: 2.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $954,801.36

Ayala Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Ayala Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ayala Pharmaceuticals Share Price & Price History

Current Price: $9.84
Price Change: Price Increase of +0.34 (3.58%)
As of 11/26/2021 01:00 AM ET

This chart shows the closing price history over time for AYLA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Black Friday Special: Could 12/1 be the most profitable event in crypto history?
Man voted "#1 Most Trusted Crypto Expert" shares his latest buy recommendation.
Click For Special

Ayala Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/24/2021Roni MamlukCEOSell33,126$18.63$617,137.38
1/20/2021Gary B GordonInsiderSell3,000$15.03$45,090.0011,520View SEC Filing Icon  
1/20/2021Roni MamlukCEOSell19,466$15.03$292,573.98179,877View SEC Filing Icon  
See Full Table
Insider Selling at Ayala Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Ayala Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Ayala Pharmaceuticals (NASDAQ:AYLA)

15.50% of Ayala Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AYLA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Ayala Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2021Wellington Management Group LLP961,609$10.91M0.0%+36.5%7.261%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace North America L.P.49,266$0.50M0.0%N/A0.372%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC10,457$0.11M0.0%N/A0.079%Search for SEC Filing on Google Icon
8/17/2021Bridgeway Capital Management LLC31,962$0.33M0.0%-8.7%0.241%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC12,407$0.14M0.0%-41.2%0.094%Search for SEC Filing on Google Icon
5/18/2021Opaleye Management Inc.108,551$1.18M0.2%N/A0.820%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley4,173$46K0.0%N/A0.032%Search for SEC Filing on Google Icon
4/22/2021Chevy Chase Trust Holdings Inc.15,000$0.16M0.0%N/A0.114%Search for SEC Filing on Google Icon
10/30/2020ARK Investment Management LLC12,063$0.14M0.0%N/A0.094%Search for SEC Filing on Google Icon
8/14/2020Jefferies Group LLC800,000$8.08M0.1%N/A6.260%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Ayala Pharmaceuticals logo
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Read More on Ayala Pharmaceuticals

Today's Range

Now: $9.84
Low: $9.00
High: $10.15

50 Day Range

MA: $11.11
Low: $9.30
High: $14.09

52 Week Range

Now: $9.84
Low: $7.74
High: $28.68

Volume

3,547 shs

Average Volume

28,587 shs

Market Capitalization

$137.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Ayala Pharmaceuticals?

Ayala Pharmaceuticals' top insider investors include:
  1. Roni Mamluk (CEO)
  2. Gary B Gordon (Insider)

Who are the major institutional investors of Ayala Pharmaceuticals?

Ayala Pharmaceuticals' top institutional shareholders include:
  1. Wellington Management Group LLP — 7.26%

Which institutional investors are buying Ayala Pharmaceuticals stock?

During the previous quarter, AYLA stock was acquired by institutional investors including:
  1. Wellington Management Group LLP
Black Friday Special: Could 12/1 be the most profitable event in crypto history?
Man voted "#1 Most Trusted Crypto Expert" shares his latest buy recommendation.
Click For Special